866-997-4948 (US-Canada Toll Free)

Avastin (Breast Cancer) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : 2011-12-31

Category :

Breast Cancer

No. of Pages : 47

Product Synopsis


GlobalDatas pharmaceuticals report, Avastin (Breast Cancer) Analysis and Forecasts to 2020 provides Avastin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Avastin including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Avastin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2007-2020 for Avastin in the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table Of Content

Table of Contents

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 GlobalData Analysis and Estimates Report Guidance 7

3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 9
3.3.1 High Prevalence 9
3.3.2 Breast Cancer: Most Frequent Cancer in Women 9
3.3.3 Increasing Breast Cancer Incidence Rate 10
3.3.4 Decreasing Breast Cancer Mortality Rate 11
3.3.5 High Survival Rates of Breast Cancer 14

4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15

5 Predictive Biomarker in the Treatment of Breast Cancer 18

6 Treatment Options of Breast Cancer 20

6.1 Stage 0 Breast Cancer: Treatment Options 20
6.2 Early Stage Breast Cancer (Excluding Stage 0) 21
6.3 Metastatic Breast Cancer (MBC) 23
6.3.1 Endocrine treatment: Adjuvant, First Line and Second Line 23
6.3.2 Cytotoxic Chemotherapy 25
6.3.3 Management of Patients with HER-2 Positive Patients 27

7 Avastin (bevacizumab) 29
7.1 Introduction 29
7.2 Mechanism of Action 29
7.3 Clinical Studies 29
7.4 Approval History of Avastin 30
7.5 Factors Affecting Sales of Avastin 31
7.5.1 Breast Cancer Market 31
7.5.2 Efficacy 31
7.5.3 Approval in Japan 31
7.5.4 Withdrawal of Approval in the US and Rejection in the UK 31
7.5.5 EMAs Verdict 31
7.6 Drug Evaluation 31
7.6.1 Drug Risk Benefit Score 31
7.6.2 Intensity of Competition 32
7.7 Sales Forecasts 32
7.7.1 Target Patient Pool of Avastin 33
7.7.2 Dosing 33
7.7.3 Market Penetration 34
7.7.4 Annual Cost of Therapy 34
7.7.5 Sales Projections of Avastin 34

8 Breast Cancer Market: Appendix 43
8.1 Market Definitions 43
8.2 Abberiviations 43
8.3 Research Methodology 43
8.3.1 Coverage 44
8.3.2 Secondary Research 44
8.3.3 Forecasting 44
8.3.4 Number of Patients Approved to take the Drug 44
8.3.5 Net Penetration of Drug 45
8.3.6 Net Annual Dosing 46
8.3.7 Annual Cost of Therapy 46
8.3.8 Primary Research 46
8.3.9 Expert Panels 46
8.4 Contact Us 47
8.5 Disclaimer 47
8.6 Sources 47

List of Tables


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Table 3: Five-Year Relative Survival Rates, By Stages 14
Table 4: Phase III Clinical Study (E2100) Results for Avastin in Metastatic Breast Cancer 29
Table 5: Approval History of Avastin 30
Table 6: Drug Risk Benefit Score of Avastin 32
Table 7: Avastin, Breast Cancer, The US, The UK, France, Germany, Italy and Spain, Sales Estimates ($m), 20072010 35
Table 8: Avastin, Breast Cancer, France, Germany, Italy, Spain and Japan, Sales Forecasts ($m), 20072020 35
Table 9: Avastin, Breast Cancer, The US, Sales Estimates ($m) 20082010 36
Table 10: Avastin, Breast Cancer, The UK, Sales Estimates ($m) 20072010 37
Table 11: Avastin, Breast Cancer, France, Sales Forecasts ($m) 2007-2020 38
Table 12: Avastin, Breast Cancer, Germany, Sales Forecasts ($m) 20072020 39
Table 13: Avastin, Breast Cancer, Italy, Sales Forecasts ($m) 20072020 40
Table 14: Avastin, Breast Cancer, Spain, Sales Forecasts ($m) 20072020 41
Table 15: Avastin, Breast Cancer, Japan, Sales Forecasts ($m) 20112020 42

List of Figures


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Top Ten Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 9
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 11
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 12: Broad Classification of Breast Cancer, By Type 15
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 14: Classification of Invasive Breast Cancer, By Stages 16
Figure 15: Classification of Invasive Breast Cancer, By Treatment 16
Figure 16: Classification of Metastatic or Advanced Breast Cancer 16
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 17
Figure 18: Classification of Locally Advanced Breast Cancer 17
Figure 19: Metastatic Breast Cancer Classification 17
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18
Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 19
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 19
Figure 23: Treatment Options, DCIS Breast Cancer 20
Figure 24: Treatment Options, LCIS Breast Cancer 21
Figure 25: Treatment Options, Stages I, II and IIIA 21
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 24
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 27
Figure 33: Drug Model Diagram of Avastin 33
Figure 34: Avastin, Breast Cancer, Global, Sales Forecasts ($m), 20072020 35
Figure 35: Avastin, Breast Cancer, The US, Sales Estimates ($m) 20082010 36
Figure 36: Avastin, Breast Cancer, The UK, Sales Estimates ($m) 20072010 37
Figure 37: Avastin, Breast Cancer, France, Sales Forecasts ($m) 2007-2020 38
Figure 38: Avastin, Breast Cancer, Germany, Sales Forecasts ($m) 20072020 39
Figure 39: Avastin, Breast Cancer, Italy, Sales Forecasts ($m) 20072020 40
Figure 40: Avastin, Breast Cancer, Spain, Sales Forecasts ($m) 20072020 41
Figure 41: Avastin, Breast Cancer, Japan, Sales Forecasts ($m) 20112020 42
Figure 42: Drug Model Diagram 45
Figure 43: Patients Approved for the Drug 46

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Solvent Based Inks Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020

    By - Transparency

    Solvent based inks are inks that have solvents as a base constituent and pigments are dissolved in it. Solvent based inks can be used on a variety of pigments and substrates. It offers, long lasting and durable prints that are also resistant to scratching and rubbing. Pigment are dissolved in solvent and dried to evaporate the solvent. This drying process can be done at room temperature or with the help of heat. Solvents used in these are alcohols, alkyl acetates, propylene glycol ethers and low molecular weight hydrocarbons. According to end user industries solvent based inks can be...

  • E-Waste Management Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth and Forecast 2014 - 2020

    By - Transparency

    The global e-waste management market is anticipated to grow during the forecast period owing to the increasing amount of e-waste generated every year. The e-waste generated should be recycled or disposed properly to protect the environment and human beings from the harmful effects of toxic elements present in it. According to Environmental Protection Agency (EPA), the amount of e-waste generated is estimated to increase between 5 to 10% annually. In 2011, the amount of e-waste recovered is approximately 5% of the total e-waste generated. Rest of the e-waste that is dumped without proper...

  • Operating Systems and Subsystems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

    By - Transparency

    Operating systems (OS) are programs that act as an interface between a computer’s hardware and its user. Subsystems are a part of larger systems such as operating systems; multiple subsystems can be loaded in the operating system. It bridges the gap between the users and the computer hardware. There are different types of operating systems based on their usage such as real-time, multi-user, distributed, embedded, single user single-task and single user multi-task. Operating systems are required in all electronic interactive systems such as mobile phones, washing machines and...